| NCT04360434 |
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT04360434 |
Recruiting |
Neurimmune AG |
2021-08-25 |
| NCT04153149 |
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT04153149 |
Recruiting |
Alnylam Pharmaceuticals |
2024-06-30 |
| NCT03997383 |
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) |
https://ClinicalTrials.gov/show/NCT03997383 |
Recruiting |
Alnylam Pharmaceuticals |
2021-10-01 |
| NCT03378453 |
Narcolepsy Protect Against Alzheimer’s Disease? |
https://ClinicalTrials.gov/show/NCT03378453 |
Completed |
University Hospital, Montpellier |
2017-11-30 |
| NCT04136184 |
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy |
https://ClinicalTrials.gov/show/NCT04136184 |
Recruiting |
Ionis Pharmaceuticals, Inc. |
2024-01-31 |
| NCT04136171 |
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM) |
https://ClinicalTrials.gov/show/NCT04136171 |
Recruiting |
Ionis Pharmaceuticals, Inc. |
2024-01-31 |
| NCT03336580 |
A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis |
https://ClinicalTrials.gov/show/NCT03336580 |
Active, not recruiting |
Prothena Biosciences Limited |
2021-05-30 |
| NCT03322319 |
Frequency of Cardiac Amyloidosis in the Caribbean’s. (TEAM Amylose) |
https://ClinicalTrials.gov/show/NCT03322319 |
Completed |
University Hospital Center of Martinique |
2015-12-02 |
| NCT03315026 |
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT03315026 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-10-31 |
| NCT03311828 |
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03311828 |
Recruiting |
City of Hope Medical Center |
2020-07-31 |
| NCT03283917 |
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT03283917 |
Recruiting |
M.D. Anderson Cancer Center |
2020-10-30 |
| NCT03236792 |
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT03236792 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2020-06-30 |
| NCT03232632 |
Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. |
https://ClinicalTrials.gov/show/NCT03232632 |
Recruiting |
University Hospital, Toulouse |
2019-09-30 |
| NCT03211676 |
Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer |
https://ClinicalTrials.gov/show/NCT03211676 |
Completed |
Poitiers University Hospital |
2018-03-14 |
| NCT03201965 |
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT03201965 |
Active, not recruiting |
Janssen Research & Development, LLC |
2020-02-14 |
| NCT03190577 |
Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology |
https://ClinicalTrials.gov/show/NCT03190577 |
Recruiting |
Nantes University Hospital |
2021-06-30 |
| NCT03129269 |
Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults |
https://ClinicalTrials.gov/show/NCT03129269 |
Recruiting |
University Hospital, Toulouse |
2018-09-30 |
| NCT03119558 |
PET/MRI Evaluation of Cardiac Amyloid |
https://ClinicalTrials.gov/show/NCT03119558 |
Completed |
Stanford University |
2018-08-23 |
| NCT03077620 |
Sleep Quality and Amyloid-Beta Kinetics |
https://ClinicalTrials.gov/show/NCT03077620 |
Recruiting |
Washington University School of Medicine |
2021-06-30 |
| NCT03019029 |
Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis |
https://ClinicalTrials.gov/show/NCT03019029 |
Enrolling by invitation |
Mayo Clinic |
2020-12-31 |
| NCT02994784 |
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients |
https://ClinicalTrials.gov/show/NCT02994784 |
Recruiting |
Boston Medical Center |
2022-01-31 |
| NCT02959489 |
Risk Evaluation and Education for Alzheimer’s Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) |
https://ClinicalTrials.gov/show/NCT02959489 |
Recruiting |
Brigham and Women’s Hospital |
2020-05-31 |
| NCT02953808 |
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects |
https://ClinicalTrials.gov/show/NCT02953808 |
Completed |
GlaxoSmithKline |
2016-12-31 |
| NCT02924272 |
Ixazomib Rollover Study |
https://ClinicalTrials.gov/show/NCT02924272 |
Active, not recruiting |
Takeda |
2021-10-01 |
| NCT02911857 |
An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes |
https://ClinicalTrials.gov/show/NCT02911857 |
Completed |
Novartis |
2017-01-27 |
| NCT02909036 |
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. |
https://ClinicalTrials.gov/show/NCT02909036 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-09-30 |
| NCT02841033 |
Daratumumab for the Treatment of Patients With AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT02841033 |
Active, not recruiting |
Boston Medical Center |
2020-06-30 |
| NCT02816476 |
Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT02816476 |
Active, not recruiting |
University Hospital, Limoges |
2019-12-31 |
| NCT02797847 |
A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02797847 |
Completed |
Alnylam Pharmaceuticals |
2018-01-12 |
| NCT02791373 |
Vinorelbine and Gemcitabine in Myeloma |
https://ClinicalTrials.gov/show/NCT02791373 |
Completed |
University Hospital Inselspital, Berne |
2017-12-31 |
| NCT02791230 |
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT02791230 |
Recruiting |
Pfizer |
2026-12-24 |
| NCT02769000 |
Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer’s |
https://ClinicalTrials.gov/show/NCT02769000 |
Active, not recruiting |
Virginia Commonwealth University |
2021-04-30 |
| NCT02775994 |
Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) |
https://ClinicalTrials.gov/show/NCT02775994 |
Recruiting |
Rabin Medical Center |
2020-01-31 |
| NCT02641145 |
Molecular Imaging of Primary Amyloid Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT02641145 |
Recruiting |
Brigham and Women’s Hospital |
2020-03-30 |
| NCT02632786 |
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT02632786 |
Completed |
Prothena Therapeutics Ltd. |
2018-03-31 |
| NCT02595983 |
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant |
https://ClinicalTrials.gov/show/NCT02595983 |
Completed |
Alnylam Pharmaceuticals |
2017-02-06 |
| NCT01659658 |
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01659658 |
Active, not recruiting |
Takeda |
2022-06-30 |
| NCT03397810 |
Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study |
https://ClinicalTrials.gov/show/NCT03397810 |
Recruiting |
University Hospital, Geneva |
2026-02-28 |
| NCT02556502 |
18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer’s Disease : a Pilot Study |
https://ClinicalTrials.gov/show/NCT02556502 |
Completed |
Central Hospital, Nancy, France |
2017-11-30 |
| NCT02510261 |
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) |
https://ClinicalTrials.gov/show/NCT02510261 |
Active, not recruiting |
Alnylam Pharmaceuticals |
2022-08-31 |
| NCT02425241 |
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination |
https://ClinicalTrials.gov/show/NCT02425241 |
Completed |
University College, London |
2016-02-29 |
| NCT02338427 |
Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis |
https://ClinicalTrials.gov/show/NCT02338427 |
Completed |
Centre Hospitalier Departemental Vendee |
2018-11-30 |
| NCT02334748 |
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies |
https://ClinicalTrials.gov/show/NCT02334748 |
Completed |
Novartis |
2018-08-31 |
| NCT02319005 |
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) |
https://ClinicalTrials.gov/show/NCT02319005 |
Completed |
Alnylam Pharmaceuticals |
2017-03-30 |
| NCT02292186 |
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis |
https://ClinicalTrials.gov/show/NCT02292186 |
Completed |
Alnylam Pharmaceuticals |
2017-02-22 |
| NCT02260466 |
Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. |
https://ClinicalTrials.gov/show/NCT02260466 |
Recruiting |
French Cardiology Society |
2021-03-31 |
| NCT02245867 |
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT02245867 |
Completed |
Columbia University |
2017-07-23 |
| NCT02207556 |
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial |
https://ClinicalTrials.gov/show/NCT02207556 |
Active, not recruiting |
Medical College of Wisconsin |
2017-07-31 |
| NCT02191826 |
Study of SOM0226 in Familial Amyloid Polyneuropathy |
https://ClinicalTrials.gov/show/NCT02191826 |
Completed |
SOM Biotech SL |
2015-11-30 |
| NCT02175004 |
Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) |
https://ClinicalTrials.gov/show/NCT02175004 |
Active, not recruiting |
Ionis Pharmaceuticals, Inc. |
2022-06-30 |
| NCT02158052 |
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease |
https://ClinicalTrials.gov/show/NCT02158052 |
Recruiting |
Massachusetts General Hospital |
2021-02-28 |
| NCT02064153 |
Studying the Effect of Dialysate Temperature on Toxin Removal and Hypotension |
https://ClinicalTrials.gov/show/NCT02064153 |
Completed |
National University Hospital, Singapore |
2014-03-31 |
| NCT02063217 |
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction |
https://ClinicalTrials.gov/show/NCT02063217 |
Completed |
Washington University School of Medicine |
2016-07-31 |
| NCT02059291 |
Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers |
https://ClinicalTrials.gov/show/NCT02059291 |
Completed |
Novartis |
2017-07-04 |
| NCT01277016 |
A Trial for Systemic Light-chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01277016 |
Completed |
European Myeloma Network |
2016-02-29 |
| NCT01273844 |
Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL) |
https://ClinicalTrials.gov/show/NCT01273844 |
Completed |
Nanjing University School of Medicine |
2016-05-12 |
| NCT02055534 |
Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis |
https://ClinicalTrials.gov/show/NCT02055534 |
Completed |
IRCCS Policlinico S. Matteo |
2013-09-30 |
| NCT02053454 |
A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT02053454 |
Completed |
Alnylam Pharmaceuticals |
2014-03-31 |
| NCT02016365 |
Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis |
https://ClinicalTrials.gov/show/NCT02016365 |
Completed |
Umeå University |
2014-12-31 |
| NCT02015312 |
A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) |
https://ClinicalTrials.gov/show/NCT02015312 |
Completed |
University Hospital Heidelberg |
2017-10-11 |
| NCT03352258 |
Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer’s Disease |
https://ClinicalTrials.gov/show/NCT03352258 |
Recruiting |
University Hospital, Geneva |
2020-12-30 |
| NCT01998503 |
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT01998503 |
Completed |
Nanjing University School of Medicine |
2013-06-30 |
| NCT01994889 |
Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT01994889 |
Completed |
Pfizer |
2018-02-07 |
| NCT01981837 |
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis |
https://ClinicalTrials.gov/show/NCT01981837 |
Completed |
Alnylam Pharmaceuticals |
2014-10-31 |
| NCT01961921 |
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) |
https://ClinicalTrials.gov/show/NCT01961921 |
Completed |
Alnylam Pharmaceuticals |
2016-07-31 |
| NCT01960348 |
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis |
https://ClinicalTrials.gov/show/NCT01960348 |
Completed |
Alnylam Pharmaceuticals |
2017-08-31 |
| NCT01864018 |
Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis |
https://ClinicalTrials.gov/show/NCT01864018 |
Active, not recruiting |
Mayo Clinic |
2021-01-01 |
| NCT01855360 |
Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT01855360 |
Completed |
Brigham and Women’s Hospital |
2015-05-31 |
| NCT01849783 |
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01849783 |
Active, not recruiting |
University of Iowa |
2020-06-30 |
| NCT01318902 |
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis |
https://ClinicalTrials.gov/show/NCT01318902 |
Completed |
Takeda |
2018-11-13 |
| NCT01821118 |
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy |
https://ClinicalTrials.gov/show/NCT01821118 |
Completed |
Pfizer |
2015-09-30 |
| NCT01815086 |
Radioimmunoimaging of Light Chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01815086 |
Completed |
University of Tennessee |
2013-07-31 |
| NCT01814839 |
A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01814839 |
Completed |
Alnylam Pharmaceuticals |
2015-04-30 |
| NCT03346135 |
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03346135 |
Recruiting |
City of Hope Medical Center |
2020-09-05 |
| NCT01789242 |
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis |
https://ClinicalTrials.gov/show/NCT01789242 |
Completed |
Criterium, Inc. |
2016-12-31 |
| NCT01777243 |
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT01777243 |
Completed |
GlaxoSmithKline |
2015-12-22 |
| NCT01758042 |
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders |
https://ClinicalTrials.gov/show/NCT01758042 |
Recruiting |
Massachusetts General Hospital |
2019-07-31 |
| NCT01737398 |
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy |
https://ClinicalTrials.gov/show/NCT01737398 |
Completed |
Ionis Pharmaceuticals, Inc. |
2017-03-03 |
| NCT01728259 |
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD |
https://ClinicalTrials.gov/show/NCT01728259 |
Active, not recruiting |
Barbara Ann Karmanos Cancer Institute |
2019-12-31 |
| NCT01707264 |
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01707264 |
Completed |
Prothena Therapeutics Ltd. |
2016-08-09 |
| NCT01683825 |
Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography |
https://ClinicalTrials.gov/show/NCT01683825 |
Recruiting |
Brigham and Women’s Hospital |
2020-06-30 |
| NCT01677286 |
Safety and Effect of Doxycycline in Patients With Amyloidosis |
https://ClinicalTrials.gov/show/NCT01677286 |
Completed |
Boston University |
2015-05-22 |
| NCT01619709 |
Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage |
https://ClinicalTrials.gov/show/NCT01619709 |
Completed |
University Hospital, Toulouse |
2017-06-30 |
| NCT01617967 |
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01617967 |
Completed |
Alnylam Pharmaceuticals |
2013-10-31 |
| NCT01570387 |
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT01570387 |
Active, not recruiting |
Boston Medical Center |
2018-11-30 |
| NCT01559077 |
Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects |
https://ClinicalTrials.gov/show/NCT01559077 |
Completed |
Alnylam Pharmaceuticals |
2012-06-30 |
| NCT01527032 |
Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01527032 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT01510613 |
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT01510613 |
Completed |
IRCCS Policlinico S. Matteo |
2016-12-31 |
| NCT01435655 |
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin |
https://ClinicalTrials.gov/show/NCT01435655 |
Completed |
Pfizer |
2014-02-28 |
| NCT01409148 |
Radioimmunoimaging of AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT01409148 |
Completed |
University of Tennessee |
2012-03-31 |
| NCT01406314 |
SAP Depleter Dose Assessment Study in Patients |
https://ClinicalTrials.gov/show/NCT01406314 |
Completed |
GlaxoSmithKline |
2012-11-14 |
| NCT01383759 |
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT01383759 |
Completed |
Memorial Sloan Kettering Cancer Center |
2019-04-30 |
| NCT01323985 |
SAP Depleter Dose Escalation Study in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01323985 |
Completed |
GlaxoSmithKline |
2011-06-30 |
| NCT04392960 |
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT04392960 |
Recruiting |
IRCCS Policlinico S. Matteo |
2023-02-28 |
| NCT04304144 |
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT04304144 |
Recruiting |
Caelum Biosciences |
2020-07-27 |
| NCT04298372 |
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium |
https://ClinicalTrials.gov/show/NCT04298372 |
Recruiting |
Seoul National University Hospital |
2021-03-15 |
| NCT04245098 |
Carpal Tunnel Syndrome and Amyloidosis |
https://ClinicalTrials.gov/show/NCT04245098 |
Recruiting |
Corporacion Parc Tauli |
2022-01-08 |
| NCT04242667 |
Penn Biobank Return of Research Results Program |
https://ClinicalTrials.gov/show/NCT04242667 |
Enrolling by invitation |
University of Pennsylvania |
2020-12-31 |
| NCT04174287 |
Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer’s Disease |
https://ClinicalTrials.gov/show/NCT04174287 |
Recruiting |
Chang Gung Memorial Hospital |
2023-03-27 |
| NCT04146480 |
The Potential Role of 18F-NaF PET/CT in Diagnosing Cardiac Amyloidosis |
https://ClinicalTrials.gov/show/NCT04146480 |
Recruiting |
Tel-Aviv Sourasky Medical Center |
2018-07-31 |
| NCT04131309 |
A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT04131309 |
Recruiting |
European Myeloma Network |
2023-01-31 |
| NCT04115956 |
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT04115956 |
Recruiting |
Oncopeptides AB |
2021-11-30 |
| NCT04105634 |
Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT |
https://ClinicalTrials.gov/show/NCT04105634 |
Active, not recruiting |
University of Pennsylvania |
2021-10-01 |
| NCT03996382 |
Prevalence of Wild Type Transthyretin Cardiac Amyloidosis in Patients Operated for Idiopathic Carpal Tunnel Syndrome |
https://ClinicalTrials.gov/show/NCT03996382 |
Recruiting |
Aarhus University Hospital Skejby |
2020-11-01 |
| NCT03969732 |
Multimodal Biomarkers for Diagnosis and Prognosis in CAA |
https://ClinicalTrials.gov/show/NCT03969732 |
Recruiting |
National Taiwan University Hospital |
2022-07-31 |
| NCT03862807 |
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant |
https://ClinicalTrials.gov/show/NCT03862807 |
Active, not recruiting |
Alnylam Pharmaceuticals |
2021-01-31 |
| NCT03779815 |
Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography |
https://ClinicalTrials.gov/show/NCT03779815 |
Completed |
Ulsan University Hospital |
2019-02-28 |
| NCT03728634 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AKCEA-TTR-LRx in Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis |
https://ClinicalTrials.gov/show/NCT03728634 |
Completed |
Ionis Pharmaceuticals, Inc. |
2020-02-20 |
| NCT03720275 |
Early and Systematic Screening in Chronic Neuropathy |
https://ClinicalTrials.gov/show/NCT03720275 |
Recruiting |
University Hospital, Bordeaux |
2020-05-27 |
| NCT03702829 |
24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients |
https://ClinicalTrials.gov/show/NCT03702829 |
Recruiting |
Brigham and Women’s Hospital |
2022-01-31 |
| NCT03678259 |
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT03678259 |
Recruiting |
University of Tennessee Graduate School of Medicine |
2021-09-01 |
| NCT03610035 |
A Study of NPT189 in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT03610035 |
Completed |
Proclara Biosciences, Inc. |
2019-02-17 |
| NCT04456582 |
Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Bidimensional Shear Wave Elastography) in Patients With Transthyretin Amyloidosis |
https://ClinicalTrials.gov/show/NCT04456582 |
Recruiting |
University of Sao Paulo General Hospital |
2021-01-31 |
| NCT03591757 |
Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) |
https://ClinicalTrials.gov/show/NCT03591757 |
Completed |
Boston University |
2019-04-26 |
| NCT03542656 |
Application of Amyloid PET in Cerebral Amyloid Angiopathy |
https://ClinicalTrials.gov/show/NCT03542656 |
Completed |
National Taiwan University Hospital |
2016-02-17 |
| NCT03499808 |
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis |
https://ClinicalTrials.gov/show/NCT03499808 |
Active, not recruiting |
Southwest Oncology Group |
2021-10-30 |
| NCT03481972 |
A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin |
https://ClinicalTrials.gov/show/NCT03481972 |
Active, not recruiting |
IRCCS Policlinico S. Matteo |
2021-04-30 |
| NCT03474458 |
A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy |
https://ClinicalTrials.gov/show/NCT03474458 |
Recruiting |
IRCCS Policlinico S. Matteo |
2021-01-31 |
| NCT03464344 |
Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy. |
https://ClinicalTrials.gov/show/NCT03464344 |
Recruiting |
University Hospital, Toulouse |
2022-10-31 |
| NCT03414632 |
Transthyretin Cardiac Amyloidosis in HFpEF |
https://ClinicalTrials.gov/show/NCT03414632 |
Recruiting |
Mayo Clinic |
2020-06-30 |
| NCT01265394 |
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects |
https://ClinicalTrials.gov/show/NCT01265394 |
Completed |
GE Healthcare |
2011-03-31 |
| NCT01222260 |
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT01222260 |
Completed |
Columbia University |
2019-03-31 |
| NCT01215747 |
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis |
https://ClinicalTrials.gov/show/NCT01215747 |
Completed |
C.T. Development America, Inc. |
2016-01-31 |
| NCT01171859 |
Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis |
https://ClinicalTrials.gov/show/NCT01171859 |
Completed |
IRCCS Policlinico S. Matteo |
2015-04-30 |
| NCT01165554 |
Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels |
https://ClinicalTrials.gov/show/NCT01165554 |
Completed |
GE Healthcare |
2011-11-30 |
| NCT01148953 |
Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01148953 |
Completed |
Alnylam Pharmaceuticals |
2012-01-31 |
| NCT01083316 |
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT01083316 |
Active, not recruiting |
Boston Medical Center |
2013-08-31 |
| NCT01078454 |
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis |
https://ClinicalTrials.gov/show/NCT01078454 |
Completed |
National Cancer Institute (NCI) |
2014-02-28 |
| NCT01072773 |
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis |
https://ClinicalTrials.gov/show/NCT01072773 |
Completed |
Mayo Clinic |
2011-03-31 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT00952237 |
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF |
https://ClinicalTrials.gov/show/NCT00952237 |
Completed |
Dartmouth-Hitchcock Medical Center |
2011-04-30 |
| NCT00928304 |
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid. |
https://ClinicalTrials.gov/show/NCT00928304 |
Completed |
Life Molecular Imaging SA |
2011-01-31 |
| NCT00925002 |
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis |
https://ClinicalTrials.gov/show/NCT00925002 |
Active, not recruiting |
Pfizer |
2020-05-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00890552 |
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT00890552 |
Completed |
Stanford University |
2012-08-31 |
| NCT00883623 |
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT00883623 |
Completed |
Heidelberg University |
2013-02-28 |
| NCT00857532 |
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson’s Disease Patients |
https://ClinicalTrials.gov/show/NCT00857532 |
Completed |
Avid Radiopharmaceuticals |
2011-11-30 |
| NCT00857415 |
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain |
https://ClinicalTrials.gov/show/NCT00857415 |
Completed |
Avid Radiopharmaceuticals |
2010-03-31 |
| NCT03584022 |
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial |
https://ClinicalTrials.gov/show/NCT03584022 |
Recruiting |
Mayo Clinic |
2020-12-31 |
| NCT02161458 |
Escitalopram Effects on CSF Amyloid Beta |
https://ClinicalTrials.gov/show/NCT02161458 |
Completed |
University of Pennsylvania |
2017-08-31 |
| NCT03252600 |
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis |
https://ClinicalTrials.gov/show/NCT03252600 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2020-09-30 |
| NCT00807872 |
Radioimmunoimaging of AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT00807872 |
Completed |
University of Tennessee |
2012-03-31 |
| NCT03759379 |
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) |
https://ClinicalTrials.gov/show/NCT03759379 |
Active, not recruiting |
Alnylam Pharmaceuticals |
2021-02-28 |
| NCT03401372 |
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients |
https://ClinicalTrials.gov/show/NCT03401372 |
Active, not recruiting |
Peking Union Medical College Hospital |
2020-12-20 |
| NCT03618537 |
Ixazomib Maintenance Study in Patients With AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT03618537 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-08-31 |
| NCT02530255 |
Telomerase Activator and Retinal Amyloid |
https://ClinicalTrials.gov/show/NCT02530255 |
Completed |
Chippewa Valley Eye Clinic |
2018-10-31 |
| NCT03860935 |
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT03860935 |
Recruiting |
Eidos Therapeutics |
2023-08-31 |
| NCT01138111 |
Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients |
https://ClinicalTrials.gov/show/NCT01138111 |
Completed |
Life Molecular Imaging SA |
2011-12-31 |
| NCT00791492 |
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy |
https://ClinicalTrials.gov/show/NCT00791492 |
Completed |
Pfizer |
2008-08-31 |
| NCT00790647 |
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00790647 |
Completed |
Boston Medical Center |
2012-12-31 |
| NCT00750282 |
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer’s Disease Compared to Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT00750282 |
Completed |
Life Molecular Imaging SA |
2010-11-30 |
| NCT00742417 |
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid |
https://ClinicalTrials.gov/show/NCT00742417 |
Completed |
Grifols Biologicals, LLC |
2011-02-28 |
| NCT00679367 |
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00679367 |
Completed |
Boston Medical Center |
2015-05-31 |
| NCT00651937 |
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden |
https://ClinicalTrials.gov/show/NCT00651937 |
Completed |
M.D. Anderson Cancer Center |
2016-01-31 |
| NCT00630864 |
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis |
https://ClinicalTrials.gov/show/NCT00630864 |
Completed |
Pfizer |
2010-01-31 |
| NCT00621400 |
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis |
https://ClinicalTrials.gov/show/NCT00621400 |
Completed |
Nantes University Hospital |
2009-12-31 |
| NCT00607581 |
Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis |
https://ClinicalTrials.gov/show/NCT00607581 |
Completed |
IRCCS Policlinico S. Matteo |
2011-12-31 |
| NCT00564889 |
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00564889 |
Completed |
Mayo Clinic |
2009-02-28 |
| NCT00558896 |
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis |
https://ClinicalTrials.gov/show/NCT00558896 |
Completed |
Mayo Clinic |
2012-09-30 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT01194791 |
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed |
https://ClinicalTrials.gov/show/NCT01194791 |
Completed |
PETHEMA Foundation |
2012-09-30 |
| NCT00520767 |
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease |
https://ClinicalTrials.gov/show/NCT00520767 |
Active, not recruiting |
Barbara Ann Karmanos Cancer Institute |
2010-10-31 |
| NCT00477971 |
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00477971 |
Completed |
Mayo Clinic |
2012-07-31 |
| NCT00458822 |
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00458822 |
Completed |
Memorial Sloan Kettering Cancer Center |
2015-03-31 |
| NCT00409175 |
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis |
https://ClinicalTrials.gov/show/NCT00409175 |
Completed |
Pfizer |
2009-05-31 |
| NCT00353392 |
Q-Switched Nd:YAG in Macular Amyloidosis |
https://ClinicalTrials.gov/show/NCT00353392 |
Completed |
Shahid Beheshti University of Medical Sciences |
2006-07-31 |
| NCT00344526 |
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis |
https://ClinicalTrials.gov/show/NCT00344526 |
Completed |
University Hospital, Limoges |
NA |
| NCT00298766 |
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis |
https://ClinicalTrials.gov/show/NCT00298766 |
Completed |
Millennium Pharmaceuticals, Inc. |
2009-07-31 |
| NCT00294671 |
The Effect of Diflunisal on Familial Amyloidosis |
https://ClinicalTrials.gov/show/NCT00294671 |
Completed |
Boston University |
2012-12-31 |
| NCT00186407 |
Autologous Stem Cell Rescue for Primary Amyloidosis |
https://ClinicalTrials.gov/show/NCT00186407 |
Completed |
Stanford University |
2008-02-29 |
| NCT00166413 |
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00166413 |
Completed |
Mayo Clinic |
2006-12-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00003353 |
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00003353 |
Completed |
Eastern Cooperative Oncology Group |
2002-12-31 |
| NCT00091260 |
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00091260 |
Completed |
Boston Medical Center |
2012-07-31 |
| NCT00003853 |
4’-Iodo-4’-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00003853 |
Completed |
National Cancer Institute (NCI) |
2000-08-31 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00075621 |
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis |
https://ClinicalTrials.gov/show/NCT00075621 |
Active, not recruiting |
Boston Medical Center |
2005-06-30 |
| NCT00064337 |
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00064337 |
Completed |
Southwest Oncology Group |
2012-05-31 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00007995 |
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00007995 |
Completed |
National Cancer Institute (NCI) |
2007-11-30 |
| NCT00002849 |
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00002849 |
Completed |
Southwest Oncology Group |
1998-12-31 |
| NCT00002810 |
High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis |
https://ClinicalTrials.gov/show/NCT00002810 |
Completed |
Temple University |
2006-05-31 |
| NCT00035334 |
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis |
https://ClinicalTrials.gov/show/NCT00035334 |
Completed |
Bellus Health Inc |
NA |
| NCT00089167 |
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis |
https://ClinicalTrials.gov/show/NCT00089167 |
Completed |
Memorial Sloan Kettering Cancer Center |
2007-12-31 |
| NCT00547365 |
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction |
https://ClinicalTrials.gov/show/NCT00547365 |
Completed |
University of Tennessee |
2011-07-31 |
| NCT00017680 |
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis |
https://ClinicalTrials.gov/show/NCT00017680 |
Completed |
Office of Rare Diseases (ORD) |
2004-04-30 |